Kairos Pharma, Ltd. (KAPA)

US · Healthcare · Biotechnology

$0.49+7.23%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-1.4M

EPS

$-0.06

EPS estimate

$-0.09

EPS came in at -0.06 against a street estimate of -0.09 — a beat of 33.3%.

Market cap

$1.5M

Forward P/E

0.0

P/B

0.41

Book value

$1.37

EPS (TTM)

$-1.82

52-week high

$7.28

52-week low

$0.42

50-day MA

$1.25

200-day MA

$2.96

Beta

1.84

Analysts rate Kairos Pharma, Ltd. a buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $49.00.

Insiders

33.61%

Institutions

7.63%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kairos Pharma, Ltd. — free to start.

Data updated 2026-11-07.